Other equities analysts have also recently issued research reports about the company. HC Wainwright set a $33.00 target price on RedHill Biopharma and gave the stock a buy rating in a research report on Friday, October 7th. Zacks Investment Research upgraded RedHill Biopharma from a hold rating to a buy rating and set a $11.00 target price on the stock in a research report on Tuesday, June 28th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $26.20.
Shares of RedHill Biopharma (NASDAQ:RDHL) traded down 1.55% during trading on Wednesday, reaching $14.05. The company had a trading volume of 15,043 shares. The firm’s market capitalization is $178.91 million. RedHill Biopharma has a 12 month low of $8.10 and a 12 month high of $16.54. The firm’s 50 day moving average price is $14.60 and its 200 day moving average price is $12.82.
RedHill Biopharma (NASDAQ:RDHL) last posted its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.52. Equities analysts predict that RedHill Biopharma will post ($2.06) EPS for the current year.
Several large investors have recently added to or reduced their stakes in RDHL. Van ECK Associates Corp boosted its stake in RedHill Biopharma by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock worth $105,000 after buying an additional 138 shares in the last quarter. Royal Bank of Canada boosted its stake in RedHill Biopharma by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock worth $259,000 after buying an additional 191 shares in the last quarter. Oppenheimer & Co. Inc. purchased a new stake in RedHill Biopharma during the second quarter worth $142,000. Finally, Ingalls & Snyder LLC purchased a new stake in RedHill Biopharma during the second quarter worth $451,000. Institutional investors and hedge funds own 15.30% of the company’s stock.
RedHill Biopharma Company Profile
Receive News & Ratings for RedHill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.